Envveno Medical Corp NVNO

$8.10 +0.06 (0.75%)

Valuation

Market cap
5,586,000
Revenue TTM
$0
Net income TTM
$-19,470,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
24,200
Avg volume
21,086
Day's range
$7.70 – $8.78
Shares out
695,000
Stochastic %K
23%
Beta
1.29
Analysts
Sell
Price target
$30.00

Price

Company profile

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an ope...

Show more

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Industry
Medical Devices
Sector
Healthcare
Phone
949 261 2900
Website
https://www.envveno.com
Address
70 Doppler, Irvine, United States

Latest news

No headlines yet.

Stocktwits

DARKP00L Oct 2, 1:25 PM
$NVNO Envveno medical's first-in-class envve system to be featured at the veins 2026 innovation summit as company advances toward u.s. pivotal trial
0 replies
DekmarTrades Oct 2, 1:25 PM
Top Gainers with Press Releases Today: $SCNX $TNMG $CYCU $NVNO
0 replies
envvenomedical Oct 2, 1:04 PM
$NVNO First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial https://envveno.com/envveno-medicals-first-in-class-envve-system-to-be-featured-at-the-veins-2026-innovation-summit-as-company-advances-toward-u-s-pivotal-trial/
0 replies
sailor7 Oct 1, 12:45 AM
$CPOP $IMCC $NVNO $RAIN IMCC has over 800% cost to borrow strong watch tomorrow
0 replies
topstockalerts Oct 1, 12:40 AM
After Hours Top Gainers PT2 $NVNO $CPOP $RYET $IMCC $RAIN
0 replies
Icemanja Sep 20, 11:27 PM
$NVNO #WTF #FACT #BS Lets start with this one for transparency. Who leaked the FDA Rejection letter the day before the PR was released. JTC or Management? FACT OR BS
0 replies
envvenomedical Sep 16, 1:29 PM
$NVNO - #WTF Rob Berman What is chronic venous insufficiency, and why does it represent a significant investment opportunity? In Episode 2 of $NVNO’s WTF: With The Facts series, CEO Rob Berman breaks down CVI, how it affects blood flow in the legs and the unmet need in severe disease. https://vimeo.com/1227148259/369c7a2dff?fl=ip&fe=ec&share=copy
1 replies
envvenomedical Sep 16, 1:25 PM
$NVNO - #WTF Rob Berman NVNO CEO Rob Berman is going direct to investors with the new With The Facts video series. The series will provide updates and insights on enVVeno’s technology, clinical programs, key milestones and more. https://vimeo.com/1227147617/4cce533da3
0 replies